Drug Discovery Today

Article	Citations
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	203
Contents page 2	196
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	182
Contents page	175
The recent progress of deep-learning-based in silico prediction of drug combination	139
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	131
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	128
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	116
Sodium ion channels as potential therapeutic targets for cancer metastasis	111
New views on endothelial dysfunction in gestational hypertension and potential therapy targets	105
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	104
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	101
Models and approaches to comprehend and address glial inflammation following spinal cord injury	99
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	98
The potential value of 5-androstenediol in countering acute radiation syndrome	95
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	95
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	91
Bio-inspired nanomaterials as novel options for the treatment of cardiovascular disease	90
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	86
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	84
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	81
Gastroretentive drug delivery systems: A holy grail in oral delivery	77
Tubulin targeting agents and their implications in non-cancer disease management	77
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	76
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	75

Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	73
Computational modeling approaches and regulatory pathways for drug combinations	73
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	73
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	71
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	71
Specificity of pharmacokinetic modeling of nanomedicines	67
General aspects of powder rheology applied to pharmaceutical formulations	66
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	66
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	66
Graph neural networks for automated de novo drug design	66
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	66
Antibody–drug conjugates: What drives their progress?	66
CIPDB: A biological structure databank for studying cation and π interactions	66
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	65
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	64
Contents page 2	64
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	60
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	60
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	58
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	58
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	56
Organoids in modelling infectious diseases	56
Overcoming the protein corona in chitosan-based nanoparticles	56
Pathogenic TDP-43 in amyotrophic lateral sclerosis	55
Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients	55
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	55
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	54
Caught between a ROCK and a hard place: current challenges in structure-based drug design	54
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	54
Targeted protein degradation: current molecular targets, localization, and strategies	53
SARS–CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights	52
Steps toward nebulization in-use studies to understand the stability of new biological entities	51
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	51
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	50
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	49
MRI assessment of cerebral perfusion in clinical trials	49
Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection	48
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	48
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	46
Biofilm control by ionic liquids	45
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	45
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	45
Molecular approaches for the treatment and prevention of Friedreich's ataxia	45
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	44
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	44
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	44
Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts	44
Recent advances towards overcoming the blood–brain barrier	44
Global or local: The future of biotech	43
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	43

Self-amplifying mRNA vaccines: Mode of action, design, development and optimization	43
Contents page 2	43
Quantum computing's potential for drug discovery: Early stage industry dynamics	42
Opioid epidemic and the urge to discover new treatment options	42
50 shades of AI in regulatory science	42
The role of gut microbial β-glucuronidase in drug disposition and development	42
UCP1 activation: Hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin	42
Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery	41
Recent advances in multitarget-directed ligands via in silico drug discovery	41
IRE1α-mediated UPR activation in gastrointestinal cancers: Adaptive mechanisms and therapeutic potential	41
Open innovation: A paradigm shift in pharma R&D?	41
Overview of new indications for novel drugs approved in China between 2018 and 2024	41
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease	40
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections	40
Cubosome-based cosmeceuticals: A breakthrough in skincare	40
Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds	39
Renal cell carcinoma therapy: Current and new drug candidates	39
Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases	39
Contents page	38
Drugs from drugs: New chemical insights into a mature concept	38
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities	38
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices	38
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets	38
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches	37
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy	37
In silico resources help combat cancer drug resistance mediated by target mutations	37
Elevating life science R&D success with AI: a framework	37
Recent advances in dual-drug co-amorphous systems	37
Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis	37
Illuminating function of the understudied druggable kinome	37
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design	36
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial	36
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus	36
Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care	36
Computational resources in the management of antibiotic resistance: Speeding up drug discovery	35
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases	35
The Unitary Patent and UPC – Implications for the pharmaceutical sector	35
dbDNA™: An advanced platform for genetic medicines	35
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy	35
Corrigendum to “Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors” [Drug Discov. Today 28(1) (2023) 103394]	35
Strategizing the human microbiome for small molecules: Approaches and perspectives	35
2023 in review: FDA approvals of new medicines	34
Artificial intelligence methods in kinase target profiling: Advances and challenges	34
Small molecules targeting canonical transient receptor potential channels: an update	34
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates	34
Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation	34
A new era for schizophrenia drug development – Lessons for the future	33
Therapeutic targeting of the complement system in ocular disease	33
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236	33
Geometric deep learning methods and applications in 3D structure-based drug design	33
Artificially engineered bacteria to treat gastrointestinal disease and cancer	33
Science of, and insights into, thermodynamic principles for dermal formulations	33
Corrigendum to “Role of transient receptor potential channels in the regulation of vascular tone” [Drug Discov. Today 29(7) (2024) 104051]	33
Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches	33
Oncological drug discovery: AI meets structure-based computational research	33
Approaches to advance drug discovery for neglected tropical diseases	32
Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy	32
Molecular medicinal insights into scaffold hopping-based drug discovery success	32
Contents page	31
Peptide-derived ligands for the discovery of safer opioid analgesics	31
Compound–protein interaction prediction by deep learning: Databases, descriptors and models	31
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs	31
The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies	31
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023	31
The expanding repertoire of covalent warheads for drug discovery	31
Expanding therapeutic potential of Bdellovibrio bacteriovorus against multidrug-resistant pathogens	31
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework	31
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery	31
Druggable genome special issue: An introduction	31
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]	30
Corrigendum to “Critical path activities in clinical trial setup & conduct – How to avoid bottlenecks and accelerate clinical trials” [Drug Discov. Today 28(10) (2023) 103733]	30
LDL receptors and their role in targeted therapy for glioma: a review	30
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics	30
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies	30
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview	30
Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression	30
The era of gene therapy: From preclinical development to clinical application	30
A pipeline analysis of advanced therapy medicinal products	30
Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals	30
Social media mining in drug development—Fundamentals and use cases	29

RhoA activation-mediated vascular permeability in capillary malformation-arteriovenous malformation syndrome: a hypothesis	29
A public–private partnership to enrich the development of in silico predictive models for pharmacokinetic and cardiotoxic properties	29
Targeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds	29
‘Home inspections’ for life sciences companies going public before clinical proof-of-concept	29
Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review	29
Publisher’s Note	29
Targeting reactive oxygen species in stem cells for bone therapy	29
Using computers to ESKAPE the antibiotic resistance crisis	29
Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art	29
Deadly interactions: Synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics	28
Nanomedicine approaches to reduce cytokine storms in severe infections	28
Orphan GPR52 as an emerging neurotherapeutic target	28
Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe	28
Drugging the entire human proteome: Are we there yet?	28
Regulating NETosis: An emerging facet of statin pleiotropy	28
IdopNetwork as a genomic predictor of drug response	28
Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis	27
Evaluating the performance of drug-repurposing technologies	27
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery	27
Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy	27
TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology	27
Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer	27
Translating precision medicine for autism spectrum disorder: A pressing need	27
Chiral-engineered supraparticles: Emerging tools for drug delivery	27
Early career researchers’ experiences in drug discovery in Africa	27
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease	27
Targeting SIRT1-regulated autophagic cell death as a novel therapeutic avenue for cancer prevention	27
Recent progress in covalent organic frameworks for cancer therapy	26
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	26
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	26
Nanophotonic waveguide-based sensing of circulating cell-free mitochondrial DNA: implications for personalized medicine	26
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	26
Therapies for Inherited Retinal Dystrophies: What is Enough?	26
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications	26
Prospects of halofuginone as an antiprotozoal drug scaffold	26
A personalized pharmaco-epistatic network model of precision medicine	26
Web resources facilitate drug discovery in treatment of COVID-19	25
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	25
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	25
Patents, trade secrets and pricing	25
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	25
Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review	25
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	25
Nanofibers as drug-delivery systems for antimicrobial peptides	25
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	25
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	25
Peptide modulators of cell migration: Overview, applications and future development	25
Can preclinical drug development help to predict adverse events in clinical trials?	25
Novel and investigational therapies for wet and dry age-related macular degeneration	24
Concepts and applications of chemical fingerprint for hit and lead screening	24
Applications of density functional theory in COVID-19 drug modeling	24
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	24
Rapid progress in neuroimaging technologies fuels central nervous system translational medicine	24
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	24
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	24
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	24
Electron diffraction: Accelerating drug development	24
New approaches for challenging therapeutic targets	24
Which cryptic sites are feasible drug targets?	24
Optical tweezers for drug discovery	24
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	24
ATP-binding cassette efflux transporters and MDR in cancer	24
Contents page	24
Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery	23
Statins and angiogenesis in non-cardiovascular diseases	23
Pharmaceutical nanocrystals: A promising approach for improved topical drug delivery	23
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis	23
Contents page	23
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	23
The role of venom proteomics and single-domain antibodies for antivenoms: Progress in snake envenoming treatment	23
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020	23
Informatic challenges and advances in illuminating the druggable proteome	23
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer	23
DDR1-targeted therapies: current limitations and future potential	23
How missing value imputation is confounded with batch effects and what you can do about it	23
Contents page 2	23
How can MSI enhance our understanding of ASO distribution?	23
Metallocompounds as anticancer agents against osteosarcoma	23
On the pivotal role of drug discovery in sustainable EU pharma reform	23
Illuminating the druggable genome: Pathways to progress	23
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2	23
Contents page	23
Extrapolation: Experience gained from original biologics	23
Corrigendum to ‘Synthetic lethality: a step forward for personalized medicine in cancer’ [Drug Discov. Today 25 (2020) 305–320]	23
The forced swim test has poor accuracy for identifying novel antidepressants	22
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy	22
Tracing drugs from discovery to disposal	22
Treating liver cancer through arginine depletion	22
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	22
Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntingtin protein	22
Impact of the diseased lung microenvironment on the in vivo fate of inhaled particles	22
Positron emission tomographic imaging in drug discovery	22
Unleashing the power of generative AI in drug discovery	22
Data considerations for predictive modeling applied to the discovery of bioactive natural products	22
Recent innovations in topical delivery for management of rheumatoid arthritis: A focus on combination drug delivery	22